Group 1 - Sanofi announced the approval of Teplizumab injection (brand name: Trelagliptin) in China for adults and children aged 8 and above with stage 2 type 1 diabetes, aimed at delaying the onset of stage 3 diabetes [1] - Teplizumab is a CD3-targeted monoclonal antibody that protects pancreatic β-cells, potentially delaying the need for long-term insulin treatment by nearly 3 years [1] - The drug was first approved by the FDA in November 2022, marking it as the first and only innovative targeted therapy to delay the onset of type 1 diabetes globally [1] Group 2 - Teplizumab has been included in the fourth batch of encouraged R&D pediatric drugs in China and is set to be implemented in Hainan Boao Lecheng International Medical Tourism Pilot Zone by July 2024 [2] - The approval of Teplizumab in China is expected to benefit a larger patient population, with the first prescriptions in Asia anticipated by June 17, 2025 [2] - Sanofi's Greater China President highlighted the company's commitment to patient-centered innovation and collaboration to enhance the type 1 diabetes prevention and treatment system in China [2]